A. Vergnenegre

TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.

TL;DR: For example, CheckMate 227 as discussed by the authors showed that nivolumab plus ipilimumab prolonged overall survival (OS) versus chemotherapy in patients with tumor programmed death-ligand 1 (PD-L1) greater than or equal to 1% or less than 1% (prespecified descriptive analysis).

TL;DR: This model provides a robust economic analysis of the cost of lung cancer management, and will be useful for assessing the economic consequences of future changes in patient management.

TL;DR: The IMpower110 trial as mentioned in this paper showed significant overall survival (OS) benefit with atezolizumab versus chemotherapy in patients with treatment-naive EGFR-and ALK-negative (wild type [WT]) metastatic NSCLC with high-programmed death-ligand 1 (PD-L1) expression (≥50% on tumor cells [TCs] or ≥10% on cancer-infiltrating immune cells [ICs), per SP142 immunohistochemistry assay; p = 0.0106).

TL;DR: CheckMate 227 met its primary endpoint of significantly improved OS with NIVO + IPI vs chemo in 1L advanced NSCLC with PD-L1 ≥ 1%, and OS was also improved with N IVO +IPI in PD- L1 Clinical trial identification NCT02477826.